INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Regeneron Pharmaceuticals, Inc. - REGN - PR Newswire
π Regeneron's stock fell 9.82% ($68.57 per share) to close at $629.68 on May 16, 2026.
π§ͺ Phase 3 trial results for fianlimab combined with cemiplimab failed to show statistical significance in progression-free survival versus pembrolizumab monotherapy.
βοΈ Pomerantz Law Firm is investigating claims of securities fraud and unlawful business practices related to the clinical data disclosure.
π The investigation was prompted by a press release issued on May 15, 2026, regarding the melanoma trial outcomes.
π©ββοΈ Investors are advised to contact Danielle Peyton at Pomerantz LLP for information about joining the class action.
Risk Factors
- Regeneron's Phase 3 trial for fianlimab in combination with cemiplimab failed to achieve statistical significance for the primary endpoint of progression-free survival.
- The company disclosed that the drug combination did not demonstrate improvement in progression-free survival compared to pembrolizumab monotherapy for metastatic melanoma patients.
- A significant stock price decline of 9.82% occurred immediately following the disclosure of the negative trial results.
- Pomerantz Law Firm is actively investigating claims of securities fraud and unlawful business practices on behalf of investors.
Full Analysis
Pomerantz Law Firm is investigating potential securities fraud and unlawful business practices on behalf of investors of Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN). The firm advises interested investors to contact their legal team regarding these claims.
The investigation stems from a May 15, 2026 press release where Regeneron disclosed that Phase 3 trial results for its fianlimab and cemiplimab combination therapy failed to meet the primary endpoint of improved progression-free survival compared to pembrolizumab monotherapy in patients with metastatic melanoma.
Following this negative clinical data disclosure, Regeneron's stock price dropped $68.57 per share, or 9.82%, closing at $629.68 on May 16, 2026. The law firm notes its extensive history in recovering multimillion-dollar damages for victims of securities fraud and corporate misconduct.
This press release serves as an investor alert regarding a potential class action lawsuit triggered by the specific clinical trial failure and the subsequent market reaction.